These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 27405391)
1. Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance. Zhang CG; Yang SD; Zhu WJ; You BG; Liu Y; Yuan ZQ; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN J Biomed Mater Res B Appl Biomater; 2017 Oct; 105(7):2093-2106. PubMed ID: 27405391 [TBL] [Abstract][Full Text] [Related]
2. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy. Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638 [TBL] [Abstract][Full Text] [Related]
3. Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug. Yang SD; Zhu WJ; Zhu QL; Chen WL; Ren ZX; Li F; Yuan ZQ; Li JZ; Liu Y; Zhou XF; Liu C; Zhang XN J Biomed Mater Res B Appl Biomater; 2017 Jul; 105(5):1114-1125. PubMed ID: 27008163 [TBL] [Abstract][Full Text] [Related]
4. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793 [TBL] [Abstract][Full Text] [Related]
5. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559 [TBL] [Abstract][Full Text] [Related]
6. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Li JM; Wang YY; Zhao MX; Tan CP; Li YQ; Le XY; Ji LN; Mao ZW Biomaterials; 2012 Mar; 33(9):2780-90. PubMed ID: 22243797 [TBL] [Abstract][Full Text] [Related]
7. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma. Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776 [TBL] [Abstract][Full Text] [Related]
8. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance. Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118 [TBL] [Abstract][Full Text] [Related]
9. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation. Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663 [TBL] [Abstract][Full Text] [Related]
10. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Gu J; Fang X; Hao J; Sha X Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500 [TBL] [Abstract][Full Text] [Related]
11. siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice. Abbasi M; Aliabadi HM; Moase EH; Lavasanifar A; Kaur K; Lai R; Doillon C; Uludağ H Pharm Res; 2011 Oct; 28(10):2516-29. PubMed ID: 21638135 [TBL] [Abstract][Full Text] [Related]
12. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR. Shen J; Wang Q; Hu Q; Li Y; Tang G; Chu PK Biomaterials; 2014 Oct; 35(30):8621-34. PubMed ID: 25002258 [TBL] [Abstract][Full Text] [Related]
13. pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-poly(D,L-lactide) for tumor-targeting and controlled delivery of doxorubicin and P-glycoprotein inhibitor. Zhao Y; Zhou Y; Wang D; Gao Y; Li J; Ma S; Zhao L; Zhang C; Liu Y; Li X Acta Biomater; 2015 Apr; 17():182-92. PubMed ID: 25612838 [TBL] [Abstract][Full Text] [Related]
14. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging. Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307 [TBL] [Abstract][Full Text] [Related]
15. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model. Tiash S; Chowdhury EH J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549 [TBL] [Abstract][Full Text] [Related]
16. Redox-Activatable ATP-Depleting Micelles with Dual Modulation Characteristics for Multidrug-Resistant Cancer Therapy. Wang H; Li Y; Zhang M; Wu D; Shen Y; Tang G; Ping Y Adv Healthc Mater; 2017 Apr; 6(8):. PubMed ID: 28152267 [TBL] [Abstract][Full Text] [Related]
17. Comb-like amphiphilic polypeptide-based copolymer nanomicelles for co-delivery of doxorubicin and P-gp siRNA into MCF-7 cells. Suo A; Qian J; Zhang Y; Liu R; Xu W; Wang H Mater Sci Eng C Mater Biol Appl; 2016 May; 62():564-73. PubMed ID: 26952460 [TBL] [Abstract][Full Text] [Related]
18. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046 [TBL] [Abstract][Full Text] [Related]
19. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway. Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650 [TBL] [Abstract][Full Text] [Related]
20. pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Benoit DS; Henry SM; Shubin AD; Hoffman AS; Stayton PS Mol Pharm; 2010 Apr; 7(2):442-55. PubMed ID: 20073508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]